NASDAQ: LYELLyell Immunopharma Inc Stock
$2.30-0.14 (-5.74%)
Updated Apr 24, 2024
LYEL Price
$2.30
Fair Value Price
$0.24
Market Cap
$584.42M
52 Week Low
$1.32
52 Week High
$3.97
P/E
-2.47x
P/B
0.89x
P/S
3,745.46x
PEG
N/A
Dividend Yield
N/A
Revenue
$130.00k
Earnings
-$234.63M
Gross Margin
100%
Operating Margin
-180,486.15%
Profit Margin
-180,486.2%
Debt to Equity
0.15
Operating Cash Flow
-$164M
Beta
1.61
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
LYEL Overview
Lyell Immunopharma Incorporated is develops T cell therapies for patients with solid tumors using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion, and Epi-R, an ex vivo epigenetic reprogramming technology to generate populations of T cells with durable stemness. The company's pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers, LYL845, that targets multiple solid tumors,; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. Lyell Immunopharma was incorporated in 2018 and is headquartered in South San Francisco, CA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how LYEL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LYEL ($2.30) is overvalued by 843.22% relative to our estimate of its Fair Value price of $0.24 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
LYEL ($2.30) is not significantly undervalued (843.22%) relative to our estimate of its Fair Value price of $0.24 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
LYEL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more LYEL due diligence checks available for Premium users.
Be the first to know about important LYEL news, forecast changes, insider trades & much more!
LYEL News
Valuation
LYEL fair value
Fair Value of LYEL stock based on Discounted Cash Flow (DCF)
Price
$2.30
Fair Value
$0.24
Overvalued by
843.22%
LYEL ($2.30) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LYEL ($2.30) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
LYEL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
LYEL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.47x
Industry
15.69x
Market
41.27x
LYEL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.89x
Industry
5.86x
LYEL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LYEL's financial health
Profit margin
Revenue
$13.0k
Net Income
-$52.9M
Profit Margin
-407,153.8%
LYEL's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
LYEL's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$750.0M
Liabilities
$95.1M
Debt to equity
0.15
LYEL's short-term assets ($554.69M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LYEL's short-term assets ($554.69M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LYEL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$40.6M
Investing
-$100.7M
Financing
$759.0k
LYEL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LYEL vs Biotech Stocks
Lyell Immunopharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.